304 related articles for article (PubMed ID: 15140973)
1. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
Augustinova H; Hoeller D; Yao F
J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein.
Yao F; Eriksson E
Antiviral Res; 2002 Feb; 53(2):127-33. PubMed ID: 11750938
[TBL] [Abstract][Full Text] [Related]
3. A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant.
Yao F; Eriksson E
Hum Gene Ther; 1999 Jul; 10(11):1811-8. PubMed ID: 10446921
[TBL] [Abstract][Full Text] [Related]
4. High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
Lu Z; Brans R; Akhrameyeva NV; Murakami N; Xu X; Yao F
J Invest Dermatol; 2009 May; 129(5):1174-84. PubMed ID: 19005489
[TBL] [Abstract][Full Text] [Related]
5. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
[TBL] [Abstract][Full Text] [Related]
6. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
7. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
Morrison LA; Knipe DM
J Virol; 1994 Feb; 68(2):689-96. PubMed ID: 8289372
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.
Keadle TL; Morrison LA; Morris JL; Pepose JS; Stuart PM
J Virol; 2002 Apr; 76(8):3615-25. PubMed ID: 11907201
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
11. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.
Akhrameyeva NV; Zhang P; Sugiyama N; Behar SM; Yao F
J Virol; 2011 May; 85(10):5036-47. PubMed ID: 21389121
[TBL] [Abstract][Full Text] [Related]
12. Herpes Simplex Virus 1 Mutant with Point Mutations in
Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.
Morrison LA; Zhu L; Thebeau LG
J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492
[TBL] [Abstract][Full Text] [Related]
14. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
Ghaemi A; Soleimanjahi H; Bamdad T; Soudi S; Arefeian E; Hashemi SM; Ebtekar M
Comp Immunol Microbiol Infect Dis; 2007 Jul; 30(4):197-210. PubMed ID: 17335902
[TBL] [Abstract][Full Text] [Related]
15. A novel tetracycline-inducible viral replication switch.
Yao F; Eriksson E
Hum Gene Ther; 1999 Feb; 10(3):419-27. PubMed ID: 10048394
[TBL] [Abstract][Full Text] [Related]
16. Protection from lethal herpes simplex virus type 1 infection by vaccination with a UL41-deficient recombinant strain.
Koshizuka T; Ishioka K; Kobayashi T; Ikuta K; Suzutani T
Fukushima J Med Sci; 2016 Jun; 62(1):36-42. PubMed ID: 26983589
[TBL] [Abstract][Full Text] [Related]
17. Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis.
Noisakran S; Campbell IL; Carr DJ
J Immunol; 1999 Apr; 162(7):4184-90. PubMed ID: 10201945
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
19. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.
Geiss BJ; Smith TJ; Leib DA; Morrison LA
J Virol; 2000 Dec; 74(23):11137-44. PubMed ID: 11070010
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge.
Jamali A; Roostaee MH; Soleimanjahi H; Ghaderi Pakdel F; Bamdad T
Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
